Three patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Nov 2028
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2012 to 2031.
US 9,376,486
Human Monoclonal Antibody with Specificity for Dengue Virus Serotype 1 E Protein and Uses Thereof
Dec 14, 2031
US 10,294,293
Human Monoclonal Antibody with Specificity for Dengue Virus Serotype 1 E Protein and Uses Thereof
Dec 14, 2031
20162020202420282031
Every computed term in this portfolio is shown above.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Dec 2031 · High confidence
Also notable
Ends Nov 2028 · High confidence
Human Monoclonal Antibody with Specificity for Dengue Virus Serotype 1 E Protein and Uses Thereof
US 9,376,486
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2031.
Method of Detecting an Amount of a Cholinesterase Inhibitor in a Sample
US 8,187,832
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2028.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 21, 2026The maintenance fee for Human Monoclonal Antibody with Specificity for Dengue Virus Serotype 1 E Protein and Uses Thereof (US 10,294,293) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Human Monoclonal Antibody with Specificity for Dengue Virus Serotype 1 E Protein and Uses Thereof | 2 in force | to Dec 2031 |
| Method of Detecting an Amount of a Cholinesterase Inhibitor in a Sample | 1 in force | to Nov 2028 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,187,832 | Method of Detecting an Amount of a Cholinesterase Inhibitor in a Sample In force · High confidence | In force | High confidence | |
| US 9,376,486 | Human Monoclonal Antibody with Specificity for Dengue Virus Serotype 1 E Protein and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,294,293 | Human Monoclonal Antibody with Specificity for Dengue Virus Serotype 1 E Protein and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 11 patents ended · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.